![1]()
News
For COVID-19 plus diabetes, glycemic control tops treatment list
June 15, 2020
Tight glucose control led to better results in patients with diabetes and COVID-19.
News
Half of type 1 diabetes patients with COVID-19 manage at home
June 12, 2020
Despite high rates of hyperglycemia and DKA, only about half of patients with type 1 diabetes and COVID-19 required hospitalization, according to data from the T1D Exchange; mortality was low.
News
‘The story unfolding is worrisome’ for diabetes and COVID-19
May 28, 2020
Diabetes Care has published a host of new articles on diabetes and COVID-19 infection, as NIDDK researchers also acknowledge risks to other organ systems from the SARS-CoV-2 virus.
![1]()
News
Sarcopenic obesity: The wasting within
May 26, 2020
Sarcopenic obesity is a form of deconditioning that occurs naturally with age.
News
COVID-19 may cause subacute thyroiditis
May 21, 2020
This is the first known case of subacute thyroiditis being associated with SARS-CoV-2 infection, according to the authors.
News
Glucose control linked to COVID-19 outcomes in largest-yet study
May 15, 2020
Wuhan researchers found preexisting type 2 diabetes worsened prognosis of COVID-19; but those whose glucose stayed “in-range” had better outcomes.
News
Societies offer advice on treating osteoporosis patients during pandemic
May 11, 2020
General and specific recommendations from leading bone health organizations shine a light on how to manage osteoporosis patients during the COVID-19 pandemic.
News
FDA approves dapagliflozin for low-EF heart failure
May 7, 2020
The approval based on DAPA-HF makes dapagliflozin (Farxiga) the only drug in its class to be indicated for heart failure in the absence of diabetes.
News
New study of diabetes drug for COVID-19 raises eyebrows
May 1, 2020
Some question the safety of AstraZeneca’s just-launched DARE-19 study testing whether dapagliflozin will reduce adverse outcomes of COVID-19.
News
SGLT2 inhibitor ertugliflozin shows no CV death or renal benefit
April 29, 2020
Merck reports topline results from ertugliflozin’s FDA-mandated cardiovascular outcomes trial.
